← Back to Search

Screening Platform for Cancer Eligibility

Phase 2

Recruiting

Research Sponsored by Hoffmann-La Roche

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen meeting criteria defined in the protocol

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 10 years

Awards & highlights

Study Summary

This trial is testing whether a person's tumor biomarker status can predict if they are eligible for a Roche clinical trial.

Who is the study for?

This trial is for people with solid tumors who have a tumor sample available and are considered candidates for an upcoming clinical trial. They must be willing to participate in the new trial. People with significant liver or heart disease, other recent cancers (except certain low-risk types), or past organ transplants cannot join.Check my eligibility

What is being tested?

The study aims to analyze participants' tumor samples to identify specific biomarkers. These findings will determine if they can enter a linked Roche clinical trial that tests new cancer treatments.See study design

What are the potential side effects?

Since this is a screening study focusing on analyzing tumor tissue rather than testing drugs, there are no direct side effects from interventions like medications. However, standard risks associated with biopsy procedures may apply.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a tumor sample preserved and ready for testing.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 10 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 10 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of participants eligible for a linked Roche clinical trial

Proportion of participants with evaluable biomarker results

Trial Design

1Treatment groups

Experimental Treatment

Group I: Non-Small Cell Lung Cancer (NSCLC)Experimental Treatment1 Intervention

Participants with NSCLC will be screened for biomarker eligibility for a linked Roche study.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheLead Sponsor

2,430 Previous Clinical Trials

1,074,397 Total Patients Enrolled

Clinical TrialsStudy DirectorHoffmann-La Roche

2,201 Previous Clinical Trials

873,732 Total Patients Enrolled

Media Library

Solid Tumors Research Study Groups: Non-Small Cell Lung Cancer (NSCLC)

Solid Tumors Clinical Trial 2023: Non-Small Cell Lung Cancer (NSCLC) Highlights & Side Effects. Trial Name: NCT05419375 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research study enrolling new participants at present?

"Yes, this research study is looking for individuals to participate and is currently enrolling patients. The trial was first announced on July 22nd, 2022 and the most recent update was November 1st, 2022."

Answered by AI

What is the size of the sample population in this research project?

"The sponsor, Hoffmann-La Roche, needs to recruit 15000 eligible patients in order to successfully carry out the trial. The clinical study will be conducted at various locations, including Thompson Cancer Survival Center in Knoxville, Tennessee and Oncology & Hematology Associates of Southwest Virginia, Inc in Blacksburg, Virginia."

Answered by AI

In how many different hospitals is this medical study being run today?

"Currently, this 18 different hospitals are running this trial. Some of the locations include Knoxville, Blacksburg and Tucson. To alleviate some stress, patients are encouraged to pick a location that is closest to them."

Answered by AI

Is it legal to market and sell this drug in the United States?

"The safety of this novel treatment falls in the middle of our 1-to-3 scale at a 2. This is due to the lack of efficacy data, as this is only a Phase 2 trial."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Screening Study for Participants With Malignant Tumors

2022. "Screening Study for Participants With Malignant Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05419375.